Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 22, 2026

Back to today

From X

@pernasresearch

Pernas Research on X

I come across a class of company every now and then that I think of as a Schrödinger company. It’s a business where the market opportunity is partly endogenous to execution. In most businesses, you can reasonably separate the opportunity from the operator: you know there’s an attractive market, and execution determines how much of it the company captures. With a Schrödinger company, the two are entangled. Only exceptional execution may prove that an attractive business opportunity exists. If it fails, you may never know whether the opportunity was flawed or the execution simply wasn’t good enough. Two examples come to mind: $sfix and $tdup. In both cases there could definitely be something there but you have to prove it. And it’s very difficult to prove it.
@DeepSailCapital

Deep Sail Capital on X

$RUM is by far the most "chasing the cool thing right now" company of any out there, and they just use massive share dilution to get it done. First they tried to get into Crypto with the Tether deal a few years ago (100m share dilution). And now they are trying to get into datacenters, with Northern Data Acquisition (120m share dilution). Today they announced they are offering a counterparty 50m shares via warrants with a strike price of $0.01 just for the commercial deal to buy their GPU services. How can anyone trust this management?
@convequity 1 click

Convequity on X

Cerebras is a taxi. NVIDIA runs the buses. Almost every confusion about $CBRS begins with reviewing the wrong vehicle. We just published Part 1 of our Cerebras deep dive: → Why wafer-scale SRAM excels at low-batch decode → Why $NVDA becomes the cheaper token factory at high concurrency → Why Cerebras was built for training—but found its future in inference → Why the two architectures are increasingly complementary, not substitutes Our conclusion: Cerebras is mostly a buy over the next 2–3 years—but demand for premium-speed inference will decide the case. The full high-level report is live. 👇 https://t.co/awUwxPUSHI

Investor Letters

All letters

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 34 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 5 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $98M
Triple S Special Situations Investing 4 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $98M
Value Investors Club

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $23M
Atrium Research - Equity Research 4 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $269M
Guardian Research 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 62 of 255

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.